<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649505</url>
  </required_header>
  <id_info>
    <org_study_id>6606</org_study_id>
    <secondary_id>NCI-2012-00809</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <nct_id>NCT01649505</nct_id>
  </id_info>
  <brief_title>Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction</brief_title>
  <official_title>Intraoperative Use of Fibrin Glue Sealant Combined With Sharp Dissection Technique as a Preventative Measure for Seromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of an alternative surgical technique
      and the use of fibrin sealant in preventing post-operative seroma formation. A seroma is a
      build-up of clear bodily fluids in a place on the body where tissue has been removed by
      surgery. Seromas can happen after breast surgeries. Seromas can appear about 7 to 10 days
      after surgery, after the drainage tubes have been removed. The breast area involved in the
      surgery may have a spot that's swollen and feels like there is liquid under the skin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate differing surgical techniques (sharp dissection v. electrosurgical, use of
      fibrin glue) in latissimus dorsi donor flap harvest and their effect, if any on the
      prevention of post-operative seromas.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients undergo sharp dissection technique with fibrin sealant closure.

      ARM II: Patients undergo standard electrocoagulation dissection technique.

      After completion of study treatment, patients are followed up for 90-180 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low patient enrollment and no clinical findings.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients in Each Arm Who Develop Post-operative Seromas</measure>
    <time_frame>Up to day 180 post-operation</time_frame>
    <description>Computed with 95% confidence interval using exact method. The difference of seroma rate in the two groups will be computed with 95% confidence interval using exact method. Two-sided Fisher's exact test will be used to evaluate whether the seroma rate are significantly different for the two treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Experienced Wound Infections, Wound Separation, or Any Other Surgical Complications</measure>
    <time_frame>Up to day 180 post-operation</time_frame>
    <description>Computed with 95% confidence interval using exact method. Two-sided Fisher's exact test will be used to evaluate whether the wound complication rate are significantly different for the two treatment groups, and the odds ratio with 95% confidence interval will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of Post-operative Drainage</measure>
    <time_frame>Up to day 10 post-operation</time_frame>
    <description>Defined as total volume of drainage recorded (in ml) by nurses while the patient is in the hospital and by patient himself/herself when discharged home, until the removal of the drain by a doctor once it reaches less than 50 ml per day. Wilcoxon rank sum test will be used to compare the drainage volume of the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious and Nonserious Adverse Events and Complications</measure>
    <time_frame>Up to day 180 post-operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Arm I (fibrin sealant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo sharp dissection technique with fibrin sealant closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (standard electrocoagulation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard electrocoagulation dissection technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fibrin sealant (Beriplast P, TISSEEL VH)</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm I (fibrin sealant)</arm_group_label>
    <other_name>Beriplast P</other_name>
    <other_name>TISSEEL VH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>breast reconstruction</intervention_name>
    <description>Undergo sharp dissection technique</description>
    <arm_group_label>Arm I (fibrin sealant)</arm_group_label>
    <other_name>Mammaplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>breast reconstruction</intervention_name>
    <description>Undergo electrocoagulation dissection technique</description>
    <arm_group_label>Arm II (standard electrocoagulation)</arm_group_label>
    <other_name>Mammaplasty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will be undergoing latissimus dorsi donor flap harvest reconstruction and
             evaluated by the Department of Plastic and Reconstructive Surgery at Oregon Health and
             Science University (OHSU)

          -  These patients will be undergoing reconstructive surgery for a mastectomy/wide local
             excision of breast cancer defect or other soft tissue defect resulting from trauma,
             infection, undesirable surgical outcome, oncologic resection, etc.

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who will not qualify for latissimus dorsi donor flap reconstruction based on
             anatomical limitations specific the subjects respectively; to be evaluated by the
             plastic surgeon

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to fibrin glue sealant

          -  Patients with evidence of hematological disorders resulting in deficient coagulation
             whereby sharp dissection would result in undesirable bleeding otherwise performed more
             safely with electrosurgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana Hansen</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2012</study_first_posted>
  <results_first_submitted>February 11, 2013</results_first_submitted>
  <results_first_submitted_qc>March 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Fibrin Sealant)</title>
          <description>Patients undergo sharp dissection technique with fibrin sealant closure.
breast reconstruction : Undergo sharp dissection technique
fibrin sealant (Beriplast P, TISSEEL VH) : Applied topically</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Standard Electrocoagulation)</title>
          <description>Patients undergo standard electrocoagulation dissection technique.
breast reconstruction : Undergo electrocoagulation dissection technique</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Fibrin Sealant)</title>
          <description>Patients undergo sharp dissection technique with fibrin sealant closure.
breast reconstruction : Undergo sharp dissection technique
fibrin sealant (Beriplast P, TISSEEL VH) : Applied topically</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Standard Electrocoagulation)</title>
          <description>Patients undergo standard electrocoagulation dissection technique.
breast reconstruction : Undergo electrocoagulation dissection technique</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients in Each Arm Who Develop Post-operative Seromas</title>
        <description>Computed with 95% confidence interval using exact method. The difference of seroma rate in the two groups will be computed with 95% confidence interval using exact method. Two-sided Fisher’s exact test will be used to evaluate whether the seroma rate are significantly different for the two treatment groups.</description>
        <time_frame>Up to day 180 post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Fibrin Sealant)</title>
            <description>Patients undergo sharp dissection technique with fibrin sealant closure.
breast reconstruction : Undergo sharp dissection technique
fibrin sealant (Beriplast P, TISSEEL VH) : Applied topically</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Standard Electrocoagulation)</title>
            <description>Patients undergo standard electrocoagulation dissection technique.
breast reconstruction : Undergo electrocoagulation dissection technique</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients in Each Arm Who Develop Post-operative Seromas</title>
          <description>Computed with 95% confidence interval using exact method. The difference of seroma rate in the two groups will be computed with 95% confidence interval using exact method. Two-sided Fisher’s exact test will be used to evaluate whether the seroma rate are significantly different for the two treatment groups.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Experienced Wound Infections, Wound Separation, or Any Other Surgical Complications</title>
        <description>Computed with 95% confidence interval using exact method. Two-sided Fisher’s exact test will be used to evaluate whether the wound complication rate are significantly different for the two treatment groups, and the odds ratio with 95% confidence interval will be computed.</description>
        <time_frame>Up to day 180 post-operation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of Post-operative Drainage</title>
        <description>Defined as total volume of drainage recorded (in ml) by nurses while the patient is in the hospital and by patient himself/herself when discharged home, until the removal of the drain by a doctor once it reaches less than 50 ml per day. Wilcoxon rank sum test will be used to compare the drainage volume of the two groups.</description>
        <time_frame>Up to day 10 post-operation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious and Nonserious Adverse Events and Complications</title>
        <time_frame>Up to day 180 post-operation</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Fibrin Sealant)</title>
          <description>Patients undergo sharp dissection technique with fibrin sealant closure.</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Standard Electrocoagulation)</title>
          <description>Patients undergo standard electrocoagulation dissection technique.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to low accrual; no participants were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Juliana Hansen</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-4834</phone>
      <email>hansenju@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

